J. Gong

发表

Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.

H. Döhner, P. Vyas, H. Kantarjian, 2021, The Lancet. Oncology.

The significance of bone marrow cell morphology and its correlation with cytogenetic features in the diagnosis of MDS-RA patients.

Dan-dan Liu, Zi X. Chen, Jinlan Pan, 2009, Leukemia research.

Mutant Isocitrate Dehydrogenase (mIDH) Inhibitors, Enasidenib or Ivosidenib, in Combination with Azacitidine (AZA): Preliminary Results of a Phase 1b/2 Study in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

P. Vyas, H. Kantarjian, C. Dinardo, 2017 .

A case of basophilic leukemia bearing simultaneous translocations t(8;21) and t(9;22).

D. Lu, J. Gong, W. Zhu, 1991, Cancer genetics and cytogenetics.

Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia

H. Döhner, P. Vyas, S. Choe, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mutant IDH (mIDH) inhibitors, ivosidenib or enasidenib, with azacitidine (AZA) in patients with acute myeloid leukemia (AML).

R. Collins, P. Vyas, H. Kantarjian, 2018 .

Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 (IDH2) Mutations: Interim Phase II Results from an Ongoing, Randomized Study

H. Döhner, P. Vyas, H. Kantarjian, 2019, Blood.

Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly diagnosed acute myeloid leukemia (ND AML).

P. Vyas, O. Frankfurt, H. Kantarjian, 2019, Journal of Clinical Oncology.

Effect of enasidenib (ENA) plus azacitidine (AZA) on complete remission and overall response versus AZA monotherapy in mutant-IDH2 (mIDH2) newly diagnosed acute myeloid leukemia (ND-AML).

H. Döhner, P. Vyas, H. Kantarjian, 2020 .

Mutant IDH1 Inhibitor Ivosidenib (IVO; AG-120) in Combination with Azacitidine (AZA) for Newly Diagnosed Acute Myeloid Leukemia (ND AML)

H. Döhner, P. Vyas, O. Frankfurt, 2019, Clinical Lymphoma Myeloma and Leukemia.

Health-Related Quality of Life (HRQoL) during Treatment with Enasidenib (ENA) Plus Azacitidine (AZA) in Patients with Newly Diagnosed Mutant IDH2 (m IDH2) Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy (IC)

P. Vyas, C. Dinardo, A. Wei, 2021, Blood.